Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification of a new aggressive axis driven by ciliogenesis and absence of VDAC1-ΔC in clear cell Renal Cell Carcinoma patients.
Fabbri L, Dufies M, Lacas-Gervais S, Gardie B, Gad-Lapiteau S, Parola J, Nottet N, Meyenberg Cunha de Padua M, Contenti J, Borchiellini D, Ferrero JM, Leclercq NR, Ambrosetti D, Mograbi B, Richard S, Viotti J, Chamorey E, Sadaghianloo N, Rouleau M, Craigen WJ, Mari B, Clavel S, Pagès G, Pouysségur J, Bost F, Mazure NM. Fabbri L, et al. Among authors: viotti j. Theranostics. 2020 Feb 3;10(6):2696-2713. doi: 10.7150/thno.41001. eCollection 2020. Theranostics. 2020. PMID: 32194829 Free PMC article.
Soluble CD146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinoma.
Dufies M, Nollet M, Ambrosetti D, Traboulsi W, Viotti J, Borchiellini D, Grépin R, Parola J, Giuliano S, Helley-Russick D, Bensalah K, Ravaud A, Bernhard JC, Schiappa R, Bardin N, Dignat-George F, Rioux-Leclercq N, Oudard S, Négrier S, Ferrero JM, Chamorey E, Blot-Chabaud M, Pagès G. Dufies M, et al. Among authors: viotti j. Theranostics. 2018 Mar 28;8(9):2447-2458. doi: 10.7150/thno.23002. eCollection 2018. Theranostics. 2018. PMID: 29721091 Free PMC article. Clinical Trial.
Resistance to lysosomotropic drugs used to treat kidney and breast cancers involves autophagy and inflammation and converges in inducing CXCL5.
Giuliano S, Dufies M, Ndiaye PD, Viotti J, Borchiellini D, Parola J, Vial V, Cormerais Y, Ohanna M, Imbert V, Chamorey E, Rioux-Leclercq N, Savina A, Ferrero JM, Mograbi B, Pagès G. Giuliano S, et al. Among authors: viotti j. Theranostics. 2019 Jan 30;9(4):1181-1199. doi: 10.7150/thno.29093. eCollection 2019. Theranostics. 2019. PMID: 30867824 Free PMC article.
CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas.
Dufies M, Giuliano S, Viotti J, Borchiellini D, Cooley LS, Ambrosetti D, Guyot M, Ndiaye PD, Parola J, Claren A, Schiappa R, Gal J, Frangeul A, Jacquel A, Cassuto O, Grépin R, Auberger P, Bikfalvi A, Milano G, Escudier B, Rioux-Leclercq N, Porta C, Negrier S, Chamorey E, Ferrero JM, Pagès G. Dufies M, et al. Among authors: viotti j. Br J Cancer. 2017 Sep 26;117(7):947-953. doi: 10.1038/bjc.2017.276. Epub 2017 Aug 29. Br J Cancer. 2017. PMID: 28850564 Free PMC article. Clinical Trial.
DPD status and fluoropyrimidines-based treatment: high activity matters too.
Chamorey E, Francois E, Etienne MC, Ferrero JM, Peyrade F, Barranger E, Bozec A, Largillier R, Cassuto O, Viotti J, Schiappa R, Milano G. Chamorey E, et al. Among authors: viotti j. BMC Cancer. 2020 May 18;20(1):436. doi: 10.1186/s12885-020-06907-0. BMC Cancer. 2020. PMID: 32423482 Free PMC article.
Impact of HPV-associated p16-expression and other clinical factors on therapeutic decision-making in patients with oropharyngeal cancer: A GETTEC multicentric study.
Culié D, Garrel R, Viotti J, Schiappa R, Chamorey E, Fakhry N, Lallemant B, Vergez S, Dupret-Bories A, Dassonville O, Poissonnet G, Santini J, Peyrade F, Benezery K, Sudaka A, Jourdan-Soulier F, Chapel F, Guelfucci B, Bozec A. Culié D, et al. Among authors: viotti j. Eur J Surg Oncol. 2018 Dec;44(12):1908-1913. doi: 10.1016/j.ejso.2018.05.022. Epub 2018 May 25. Eur J Surg Oncol. 2018. PMID: 29871820
Upfront surgery or definitive radiotherapy for patients with p16-negative oropharyngeal squamous cell carcinoma. A GETTEC multicentric study.
Culié D, Viotti J, Modesto A, Schiappa R, Chamorey E, Dassonville O, Poissonnet G, Guelfucci B, Bizeau A, Vergez S, Dupret-Bories A, Garrel R, Fakhry N, Santini L, Lallemant B, Chambon G, Sudaka A, Peyrade F, Saada-Bouzid E, Benezery K, Jourdan-Soulier F, Chapel F, Ramay AS, Roger P, Galissier T, Coste V, Ben Lakdar A, Guerlain J, Temam S, Mirghani H, Gorphe P, Bozec A. Culié D, et al. Among authors: viotti j. Eur J Surg Oncol. 2021 Feb;47(2):367-374. doi: 10.1016/j.ejso.2020.07.034. Epub 2020 Sep 10. Eur J Surg Oncol. 2021. PMID: 33004271
Metachronous second primary neoplasia in oropharyngeal cancer patients: Impact of tumor HPV status. A GETTEC multicentric study.
Milliet F, Bozec A, Schiappa R, Viotti J, Modesto A, Dassonville O, Poissonnet G, Guelfucci B, Bizeau A, Vergez S, Dupret-Bories A, Garrel R, Fakhry N, Santini L, Lallemant B, Chambon G, Sudaka A, Peyrade F, Saada-Bouzid E, Benezery K, Jourdan-Soulier F, Chapel F, Sophie Ramay A, Roger P, Galissier T, Coste V, Ben Lakdar A, Guerlain J, Temam S, Mirghani H, Gorphe P, Chamorey E, Culié D. Milliet F, et al. Among authors: viotti j. Oral Oncol. 2021 Nov;122:105503. doi: 10.1016/j.oraloncology.2021.105503. Epub 2021 Sep 6. Oral Oncol. 2021. PMID: 34500315
38 results